beat365亚洲版官网
About Hinova
Our Company
Executive Team
Partnerships
Contact Us
Innovation
Therapeutic Areas
R&D Platforms
Pipeline & Programs
Collaboration
News
Press Releases
Careers
Working at Hinova
Employee Benefits
Open Positions
EN
CH
About Hinova
Our Company
Executive Team
Partnerships
Contact Us
Innovation
Therapeutic Areas
R&D Platforms
Pipeline & Programs
Collaboration
News
Press Releases
Careers
Working at Hinova
Employee Benefits
Open Positions
Integrity,Innovation,Reliability,Responsibility
Press Releases
Home
News
Press Releases
Media and Public Relations
media@hinovapharma.com
Hinova Announces First Patient Dosed in a Phase I Clinical Trial of HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
2022.01.20
加载更多